Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer (Review)

4Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Anthracycline drugs are considered to be pivotal drugs in numerous chemotherapy regimens for breast cancer. However, the cardiotoxicity associated with the treatment is an important issue to be addressed. With the emergence of increasingly diverse antitumor drugs, anthracycline-free therapies are able to reduce the cardiotoxicity caused by anthracycline drugs while ensuring that a therapeutic effect is achieved. In the present review, anthracycline-free oncological therapy regimens for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the associated cardiovascular toxicity are discussed, as well as some monitoring strategies. It is recommended that patients with HER2-positive breast cancer patients should receive adjuvant chemotherapy with single or dual-targeted therapy, with or without endocrine therapy according to the hormone receptor status determined by immunohistochemical examination. The main side effects of targeted therapy include cardiac dysfunction, hypertension and arrhythmia. According to individual risk stratification, it is recommended that patients should be periodically monitored using echocardiography, electrocardiography and serum markers, to enable the timely detection of the cardiovascular adverse reactions associated with tumor treatment, thereby preventing the morbidity and mortality caused by the cardiotoxicity of these drugs.

References Powered by Scopus

Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2

10136Citations
N/AReaders
Get full text

Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging

6008Citations
N/AReaders
Get full text

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

4525Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

136Citations
N/AReaders
Get full text

Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data

17Citations
N/AReaders
Get full text

Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Guan, J., & Zhang, M. (2021, February 1). Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer (Review). Oncology Letters. Spandidos Publications. https://doi.org/10.3892/ol.2020.12361

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

44%

Researcher 3

33%

Professor / Associate Prof. 1

11%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

63%

Pharmacology, Toxicology and Pharmaceut... 2

13%

Economics, Econometrics and Finance 2

13%

Agricultural and Biological Sciences 2

13%

Save time finding and organizing research with Mendeley

Sign up for free